Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger CCHC domain-containing protein 12 (ZCCHC12) is a transcriptional coactivator characterized by a CCHC-type zinc finger domain, primarily localizing to the nucleus.[4][6] Its principal function is to enhance bone morphogenetic protein (BMP) signaling by interacting with SMAD1 and CBP within transcriptional complexes, thereby influencing the expression of BMP-responsive genes, particularly in cholinergic neurons.[5][4][2] The protein is implicated in neurodevelopment, with genetic variations linked to X-linked intellectual disability and potentially other neurodevelopmental disorders.[4] ZCCHC12 is also identified as a metastasis-related oncogene in papillary thyroid cancer[1] and has been proposed as a marker for Cajal–Retzius cells and endometrial receptivity.[2] It does not function as a classic therapeutic target, receptor, or enzyme, and there are no approved drugs that directly act on ZCCHC12.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger CCHC domain-containing protein 12 (ZCCHC12).